πŸ‡ΊπŸ‡Έ FDA
Patent

US 11725034

IL2 agonists and methods of use thereof

granted A61KA61K2039/505A61K2039/585

Quick answer

US patent 11725034 (IL2 agonists and methods of use thereof) held by REGENERON PHARMACEUTICALS, INC. expires Mon Aug 10 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Aug 15 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 10 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
30
CPC classes
A61K, A61K2039/505, A61K2039/585, A61K2239/50, A61K2239/55